Intervacc AB (publ)

Stockholm Stock Exchange IVACC.ST

Intervacc AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -207.96 K

Intervacc AB (publ) Net Cash Used For Investing Activities is USD -207.96 K for the year ending December 31, 2023, a 64.49% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Intervacc AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -585.61 K, a 77.00% change year over year.
  • Intervacc AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -2.55 M, a -86.45% change year over year.
  • Intervacc AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -1.37 M, a 67.06% change year over year.
  • Intervacc AB (publ) Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -4.15 M, a -57.85% change year over year.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
Loading...
SV Wall Street
Stockholm Stock Exchange: IVACC.ST

Intervacc AB (publ)

CEO Mr. Jonas Sohlman
IPO Date April 7, 2017
Location Sweden
Headquarters Västertorpsvägen 135
Employees 15
Sector Healthcare
Industries
Description

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.

Similar companies

SECARE.ST

Swedencare AB (publ)

USD 4.31

-4.27%

GENO.ST

Genovis AB (publ.)

USD 2.25

-17.68%

ONCO.ST

Oncopeptides AB (publ)

USD 0.16

9.53%

KAMBI.ST

Kambi Group plc

USD 10.76

-2.56%

StockViz Staff

February 5, 2025

Any question? Send us an email